TABLE 2

Geometric mean fold rises of pneumococcal OPA GMTs for the evaluable immunogenicity populationa

SerotypeData by age group (yr)b:
50–64 (n = 137–153)≥65 (n = 137–158)
Prevaccination GMTPostvaccination GMTGMFR95% CIPrevaccination GMTPostvaccination GMTGMFR95% CI
1612121.316.17, 28.1678411.78.70, 15.82
378812.59.77, 16.0511897.86.03, 10.02
4311,76757.736.40, 91.36581,15919.913.23, 29.88
5828137.326.06, 53.471128126.218.74, 36.72
6A563,51262.339.00, 99.361143,27328.719.76, 41.70
6B2374,29018.111.61, 28.153923,6919.46.61, 13.45
7F703,02543.226.94, 69.171241,92215.510.05, 23.80
9V2682,3478.85.72, 13.431941,3967.24.72, 10.98
142861,5185.33.73, 7.563821,3113.42.58, 4.56
18C693,07044.328.19, 69.511542,15213.99.21, 21.09
19A511,54230.021.19, 42.501071,19611.27.99, 15.69
19F251,07842.828.33, 64.67541,12020.813.38, 32.29
23F1488163.643.16, 93.752692335.824.16, 52.95
  • a OPA, opsonophagocytic activity; GMT, geometric mean titer.

  • b n values for the age groups reflect the numbers of subjects with valid and determinate assay results for the specified serotype at both the prevaccination and postvaccination blood draws. The GMTs and geometric mean fold rises (GMFRs) were calculated using all subjects with available data for both the prevaccination and postvaccination blood draws. The 95% confidence intervals (CIs) are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers, or the mean fold rise.